106th Day Of Lockdown

Maharashtra2237241231929448 Tamil Nadu118594711161636 Delhi102831742173165 Gujarat37636267441978 Uttar Pradesh2996819627313 Telangana2761216287313 Karnataka2681511100417 West Bengal2383715790804 Rajasthan2140416575472 Andhra Pradesh211979745252 Haryana1799913645279 Madhya Pradesh1562711768622 Bihar12525933898 Assam12523833016 Odisha10097670354 Jammu and Kashmir89315399143 Punjab67494554175 Kerala5895345228 Chhatisgarh3415272814 Uttarakhand3230262143 Jharkhand3018210422 Goa190311568 Tripura171612481 Manipur14307710 Himachal Pradesh107876410 Puducherry104351714 Nagaland6443030 Chandigarh4924017 Arunachal Pradesh270922 Mizoram1971390 Sikkim125650 Meghalaya94432
Lifestyle Health and Wellbeing 08 Feb 2018 US FDA approves Gile ...

US FDA approves Gilead triple HIV drug

REUTERS
Published Feb 8, 2018, 9:54 am IST
Updated Feb 8, 2018, 9:54 am IST
However, rival ViiV Healthcare, quickly filed a lawsuit alleging that Gilead was infringing patents on ViiV’s dolutegravir.
known as IQVIA.  The new Gilead drug’s label includes a boxed warning that use could worsen hepatitis B infection in certain patients. (Photo: Pixabay)
 known as IQVIA. The new Gilead drug’s label includes a boxed warning that use could worsen hepatitis B infection in certain patients. (Photo: Pixabay)

The US Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc’s once-daily, triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

Biktarvy combines new integrase inhibitor bictegravir with Descovy, an older medication that combines nucleoside reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide.

 

However, rival ViiV Healthcare, a joint venture majority-owned by GlaxoSmithKline Plc with Pfizer Inc and Shionogi Ltd, quickly filed a lawsuit alleging that Gilead was infringing patents on ViiV’s dolutegravir, a component of the venture’s triple-drug HIV treatment Triumeq.

Viiv is seeking “financial redress,” but is not asking for an injunction against sales of Biktarvy, according to Glaxo spokeswoman Sarah Spencer.

Gilead, in an emailed statement, said it remained ”steadfast in our opinion that Biktarvy does not infringe ViiV’s U.S. patent, and that the court challenge did not affect the U.S. availability of the drug.

“We believe that a modest royalty could be possible far down the road if Gilead were to lose” the patent case, Jefferies analyst Michael Yee said in a research note.

Wall Street analysts, on average, forecast Biktarvy sales of around $1 billion this year, rising to a peak of nearly $5 billion annually by 2024, according to Thomson Reuters I/B/E/S.

Dolutegravir, sold under the brand name Tivicay and as a component of Triumeq, is a key growth driver for Glaxo, posting fiscal 2017 sales of nearly 4 billion pounds ($5.6 billion).

The Gilead drug’s wholesale price, about $36,000 a year, is in line with current therapies, according to Guggenheim Securities.

The global market for HIV drugs could reach as high as $40 billion a year by 2021, according to pharmaceutical data company Quintiles IMS Institute, now known as IQVIA.

The new Gilead drug’s label includes a boxed warning that use could worsen hepatitis B infection in certain patients.

ViiV said it would seek to prove that Biktarvy infringed ViiV’s U.S. and Canadian patents covering dolutegravir and many other compounds that include dolutegravir’s unique chemical scaffold. The U.S. case was filed in the U.S. District Court for the District of Delaware and the Canadian case in the Canadian Federal Court in Toronto.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT